Compare · MRNA vs XLRN
MRNA vs XLRN
Side-by-side comparison of Moderna Inc. (MRNA) and Acceleron Pharma Inc. (XLRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and XLRN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $80.65B.
- MRNA has hit the wire 16 times in the past 4 weeks while XLRN has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 10 for XLRN).
- Company
- Moderna Inc.
- Acceleron Pharma Inc.
- Price
- -
- -
- Market cap
- $80.65B
- -
- 1M return
- -18.99%
- -
- 1Y return
- +791.08%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2013
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 10
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- President Stephen Hoge exercised 152,905 shares at a strike of $12.21, sold $16,900,019 worth of shares (78,375 units at $215.63) as part of a pre-agreed trading plan and gifted 400,000 shares, decreasing direct ownership by 20% to 1,311,095 units (SEC Form 4)
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest XLRN
- Qiming Venture Partners USA Announces $260 Million US Healthcare Fund III and Addition of New Partner, Isaac Ciechanover
- SEC Form 15-12B filed by Acceleron Pharma Inc.
- SEC Form SC 13D/A filed by Acceleron Pharma Inc. (Amendment)
- SEC Form 4: Zakrzewski Joseph S closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Malik Kemal closing all direct ownership in the company (withholding obligation)
- SEC Form 4: Hite Christopher closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Smith Karen L. closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Mccourt Thomas A closing all direct ownership in the company (tax liability)
- SEC Form 4: Kearney Terrence C closing all direct ownership in the company (for tax liability)
- SEC Form 4: Hamill Laura closing all direct ownership in the company (tax liability)